Slimming Injections: GLP-1 Agonists, Fat-Dissolving Injections, and What the Evidence Shows

"Slimming injections" covers two distinct categories of medical intervention with entirely different mechanisms, evidence bases, and regulatory frameworks. Understanding which category is being discussed is essential — the evidence, risks, and appropriate use cases are not interchangeable.

Category 1: Injectable Weight Loss Medications (GLP-1 Receptor Agonists)

These are prescription-only medications injected subcutaneously (under the skin) on a weekly basis that act systemically to reduce appetite and body weight.

Semaglutide (Wegovy)

Mechanism: Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide 1, a gut hormone that suppresses appetite via hypothalamic circuits, slows gastric emptying to extend satiety, and modulates food reward pathways.

Evidence:

• STEP 1 trial (NEJM 2021, n=1,961, 68 weeks): mean weight loss of 14.9% body weight vs. 2.4% placebo. 86% achieved ≥5% weight loss; 48% achieved ≥15%.
• STEP 4 (JAMA 2021): discontinuation of semaglutide after 20 weeks resulted in weight regain of approximately two-thirds of lost weight over the following year — demonstrating that continued use is required to maintain benefit.

UK regulatory status: Wegovy is licensed by the MHRA for adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one comorbidity. NICE TA875 (2023) recommended it within NHS specialised weight management services.

Dose: Weekly subcutaneous injection; escalated from 0.25mg to 2.4mg over 16 weeks.

Side effects: Nausea (44%), vomiting (24%), diarrhoea (30%), constipation (24%) — predominantly gastrointestinal during dose escalation, typically improving with sustained use. Rare but serious: pancreatitis, gallstones (6.1% vs. 2.6% placebo), and — based on animal data — potential thyroid C-cell effects (contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2 syndrome).

Tirzepatide (Mounjaro/Zepbound)

Mechanism: Dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist — activates both receptors simultaneously, with evidence of greater weight loss than GLP-1 agonists alone.

Evidence:

• SURMOUNT-1 trial (NEJM 2022, n=2,539, 72 weeks): mean weight loss of 20.9% at 15mg dose; 63% achieved ≥20% weight loss. Substantially greater than semaglutide in trial context (no published head-to-head RCT, but effect sizes consistently larger).
• SURMOUNT-2 (people with T2D): 15.7% mean weight loss at 15mg.

UK regulatory status: Mounjaro (tirzepatide) received MHRA approval and NICE positive guidance for obesity in 2024. NHS access is being rolled out through specialist services.

Liraglutide (Saxenda)

An older, daily-injection GLP-1 agonist with more established but smaller effect sizes than semaglutide.

Evidence: SCALE Obesity (NEJM 2015): mean weight loss of 8.4% vs. 2.8% placebo at 56 weeks. Less effective than Wegovy but established safety record. Available in UK via prescription.

Category 2: Fat-Dissolving Injections (Localised Adipolysis)

These are injected directly into targeted fat deposits to reduce localised fat volume. They do not produce systemic weight loss.

Deoxycholic Acid (Belkyra/Kybella)

Mechanism: Deoxycholic acid is a naturally occurring bile acid. When injected into subcutaneous fat, it disrupts adipocyte cell membranes, causing cell death (adipocytolysis). The debris is cleared by the lymphatic system over 4–8 weeks.

Evidence:

• REFINE-1 and REFINE-2 trials (Dermatologic Surgery 2015): treatment with deoxycholic acid produced significant reduction in submental fat (under the chin) compared to placebo — 79.3% patient satisfaction vs. 35.2% placebo. Regulatory approval is specifically for submental fat.
• Kybella is FDA-approved (US); Belkyra is licensed in the UK for submental fat reduction only.

Important limitations:

• Does not produce weight loss — treats localised fat volume only
• Multiple sessions required (typically 4–6) spaced 4 weeks apart
• Swelling, bruising, and numbness are expected in the treatment area (up to 6 weeks)
• Marginal mandibular nerve injury (affecting smile) is a rare complication requiring experienced injector
• Expensive: £600–£1,200+ per treatment session in UK private clinics
• Does not prevent fat return if overall energy balance is not addressed

Phosphatidylcholine/Deoxycholic Acid Combinations

Mesotherapy cocktails — often marketed as "fat-dissolving injections" — commonly combine phosphatidylcholine (PC) and deoxycholic acid or other lipophilic compounds. Only deoxycholic acid alone has robust RCT evidence; PC combinations are widely performed but have weaker evidence and are not licensed for fat dissolution in the UK.

What "Slimming Injections" Are Not

Lipotropic injections (B12, methionine, inositol, choline combinations): No RCT evidence for weight loss. B12 injections correct B12 deficiency in deficient individuals but do not boost metabolism or cause fat loss in people with adequate B12. Widely available in UK private aesthetics clinics; no MHRA-licensed product for weight loss indication.

Vitamin cocktail injections: No evidence for weight loss or metabolic enhancement in people without nutrient deficiency.

Choosing Between Options: Key Considerations

Medical supervision is required for all injectable weight loss treatments. GLP-1 agonists are prescription medications with side effect profiles that require clinical monitoring. Fat-dissolving injections should be performed by clinicians with appropriate training, not non-medical aesthetics practitioners.

If you are interested in injectable weight loss treatment, start with your GP, who can assess eligibility for NHS pathways and provide clinical guidance on which option is appropriate for your circumstances.

Disclaimer: This article is for informational and educational purposes only. Prescription medications require clinical assessment and prescription. Never obtain injectable medications without a prescription from a registered UK clinician.